Mitochondrial replacement techniques (MRT) are designed to prevent the transmission of mitochondrial DNA (mtDNA) diseases from mother to child, but the techniques raise ethical, social, and policy issues. In the Institute of Medicine report Mitochondrial Replacement Techniques: Ethical, Social, and Policy Considerations, an expert committee concludes that it is ethically permissible to conduct clinical investigations of MRT subject to certain conditions and principles. This action guide is intended for those who may plan to conduct or oversee potential MRT investigations and lays out the conditions and principles offered by the committee to guide the conduct and oversight of these investigations. Selected material from five of the report's recommendations is presented below. For the complete text of the recommendations, and to read the full report, please visit nas.edu/MitoDNAEthics.
Conditions for ethical MRT first-in-human clinical investigations
The committee recommends that FDA only consider initial MRT clinical investigations if and when certain conditions can be met, including:
• limiting initial investigations to women who otherwise are at risk of transmitting a serious mtDNA disease, where the mutation's pathogenicity is undisputed and the clinical presentation of the disease is predicted to be severe, as characterized by early mortality or substantial impairment of basic function; • confirming that if the intended mother at risk of transmitting mtDNA disease is also the woman who will carry the pregnancy, professional opinion determines that she would be able to complete a pregnancy without significant risk of serious adverse consequences to her health or the health of the fetus; 
Informed consent
The informed consent of those deemed research participants in MRT clinical investigations would be required pursuant to federal guidelines and applicable state laws and institutional practices. The committee concludes that the nature of the MRT consent process for intended parents would need to reflect a research protocol that had been crafted with the health and well-being of future children in mind. In addition, best-practice consent processes should be followed for individuals who provide gametes, and the informed consent process for MRT should reflect the novel aspects of the technique to be employed. (See Recommendation 5 in the full report for complete text.)
Long-term follow-up and monitoring
The committee recommends that FDA's overall plan for review and possible approval and subsequent marketing of MRT should include a requirement that sponsors design, fund, and commit to long-term monitoring of children born as a result of MRT, with a plan for periodic review of the long-term follow-up data. (See Recommendation 6 in the full report for complete text.)
To read the full report and to view related resources, please visit nas.edu/MitoDNAEthics.
